CD84 and psoriasis: In psoriasis, a pharmacogenetic study has been conducted in a white population (from the Netherlands) in which the CD84 rs6427528-AG genotype was associated with a better response (ΔPASI at 12 weeks) to treatment with ETN (25 patients with 161 ETN episodes; beta = −2.028, 95% CI = −3.794–0.261, p = 0.025) [29].